You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 202321 - 202330 of 207699 results
  1. Development of SVAD System for HF Therapy

    SBC: SCR, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): The objective of this proposal is to complete the engineering development and pre-clinical testing of the SCR SVAD system to provide partial cardiac assist in patients with less advanced stage heart failure (HF). HF isincreasing worldwide and represents a major burden in terms of health care resources and costs. Despite advances in medical care, prognosis with ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Semiconductor Electronic Label-Free Assay (SELFA) for Diagnosing Heart Disease

    SBC: SELFA, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Cardiovascular disease is the leading cause of morbidity and mortality worldwide. In United States and Europe alone, about 15 million patients are annually admitted to emergency departments with acute coronary syndrome.These patients are immediately screened for potential acute myocardial infarction (AMI) via electrocardiogram and biomarker detection in blood s ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Reducing heart failure re-admissions by enhancing sleep apnea treatment adherence

    SBC: AIRCARE LABS, LLC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Hospital re-admission can be devastating for patients and carries significant financial burdens for health care systems. In 2013, the recently implemented Medicare Hospital Readmissions Reduction Program imposed 227 million in penalties on 2,225 hospitals. Medicare has focused on heart failure diagnoses because it is one of the most common causes of admission ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. User-driven Tool for Bilingual Clinical Dialogs and Medical Language Acquisition

    SBC: Transcendent International, LLC            Topic: NIMHD

    PROJECT SUMMARY Persistent disparities in healthcare access hinder the nation's 26 million individuals with limited English proficiency (LEP) from receiving quality care and, as a result, from achieving optimal health outcomes. Patients who struggle to understand their care providers report difficulty navigating both administrative and clinical procedures and experience significantly higher r ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. A Data-driven Approach to Improve Nursing Workflow and Patient-centered Care

    SBC: Transcendent International, LLC            Topic: NIMHD

    DESCRIPTION (provided by applicant): Patient-centered care recognizes patients' desires, opinions, and preferences as equal in importance to those of healthcare professionals, and emphasizes the need to educate and empower patients to play an active role in their care. The achievement of patient-centered care is associated with increased patient and provider satisfaction, improved health outc ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. FASTCOUNT Next generation stereology platform for fast, accurate 3D cell counting

    SBC: MICROBRIGHTFIELD, LLC            Topic: NIMH

    DESCRIPTION (provided by applicant): Stereologic cell counting has revolutionized the field of neuroscience over the last 20 years, and numerous studies highlighting the impact of stereologic cell counting in basic neuroscience and pharmaceutical and biotechnology research continue to be published. A single study, however, may take months since investigators must decide by visual inspection whethe ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Development of selective Cav3 channel blockers for treatment of neuropathic pain

    SBC: AFASCI, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): Millions of Americans suffer from chronic neuropathic pain, which is often refractory to current treatment. In search of a solution to this problem of chronic, untreatable pain, we intend to develop a new analgesic therapy based on modulation of the T-type Ca2+ channel. T-type Ca2+ channels play key roles in pain signaling. The Cav3 family of channels is invo ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a turnkey system for assessing forelimb function in rats and mice.

    SBC: VULINTUS, INC            Topic: NINDS

    DESCRIPTION (provided by applicant): Millions of Americans are affected by neurological disorders such as stroke and spinal cord injury. These disorders often result in impaired motor function and lead to significant disability amongst those affected. Despite major efforts to develop therapies to alleviate the burden of these disorders, virtually all promising preclinical therapies fail to success ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Novel Anti-LPA Antibody for the Treatment of Traumatic Brain Injury

    SBC: LPATH THERAPEUTICS, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): There are 1.7 million cases of Traumatic Brain Injury (TBI) per year in the U.S. with 125,000 having permanent disability. To date, there are no FDA-approved drugs for treating TBI. Lpath, Inc. has developed a novel anti-LPA (lysophosphatidic acid) antibody therapeutic that holds great promise as a treatment for TBI patients. LPA is an endogenous bioactive lip ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Rapid Magnetomotive Thrombolysis for Stroke

    SBC: Pulse Therapeutics, Inc.            Topic: NINDS

    DESCRIPTION (provided by applicant): Acute ischemic stroke (AIS) is the result of a blood clot in a cerebral artery. It remains a leading killer and the leading cause of long-term disabilit, annually impacting over 700,000 Americans [10]. Because brain tissue rapidly dies, time to reperfusion is critical in both preventing death and improving neurological outcomes. While current annual costs relat ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government